Cytoprotection by pyruvate through an anti-oxidative mechanism in cultured rat calvarial osteoblasts

Histology and Histopathology

Volumn 21, Issue 7-9, 2006, Pages 969-977

  Moriguchi, N ^a   Hinoi, E ^a   Tsuchihashi, Y ^a   Fujimori, S ^a   Iemata, M ^a   Takarada, T ^a   Yoneda, Yukio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Hydrogen peroxide; Osteoblasts; Pyruvate; Reactive oxygen species; Viability

Indexed keywords

ACETIC ACID; CYSTEINE; GLUTATHIONE; HYDROGEN PEROXIDE; INSULIN; LACTIC ACID; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CALVARIA; CELL CULTURE; CELL DEATH; CELL MATURATION; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG MECHANISM; ENERGY METABOLISM; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; NORTHERN BLOTTING; OSTEOBLAST; OXIDATIVE STRESS; RAT;

ANIMALS; ANTIOXIDANTS; CELL SURVIVAL; CELLS, CULTURED; CYSTEINE; GLUTATHIONE; HYDROGEN PEROXIDE; IMMUNOHISTOCHEMISTRY; MODELS, BIOLOGICAL; OSTEOBLASTS; PYRUVIC ACID; RATS; REACTIVE OXYGEN SPECIES;

EID: 33746159261     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Basu S., Michaelsson K., Olofsson H., Johansson S. and Melhus H. (2001). Association between oxidative stress and bone mineral density. Biochem. Biophys. Res. Commun. 288, 275-279.
2. Bunton C.A. (1949). Oxidation of α-diketones and α-keto-acids by hydrogen peroxide. Nature 163, 444.
3. Cappuccio F.P., Meilahn E., Zmuda J.M. and Cauley J.A. (1999). High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of osteoporotic fractures research group. Lancet 354, 971-975.
4. Christensen J.O. and Svendsen O.L. (1999). Bone mineral in pre- and postmenopausal women with insulin-dependent and non-insulin-dependent diabetes mellitus. Osteoporos. Int. 10, 307-311.
5. Desagher S., Glowinski J. and Premont J. (1997). Pyruvate protects neurons against hydrogen peroxide-induced toxicity. J. Neurosci. 17, 9060-9067.
6. Fenton H.J.H. (1894). Oxidation of tartaric acid in the presence of iron. J. Chem. Soc. 65, 899-910.
7. Halliwell B. and Whiteman M. (2004). Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br. J. Pharmacol. 142, 231-255.
8. Hamerman D. (2005). Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies. QJM 98, 467-484.
9. Hinoi E., Fujimori S., Takemori A. and Yoneda Y. (2002). Cell death by pyruvate deficiency in proliferative cultured calvarial osteoblasts. Biochem. Biophys. Res. Commun. 294, 1177-1183.
10. Hinoi E., Fujimori S. and Yoneda Y. (2003). Modulation of cellular differentiation by N-methyl-D-aspartate receptors in osteoblasts. FASEB J. 17, 1532-1534.
11. Holleman A.F. (1904). Notice sur l'action de l'eau oxygenee sur les acides α-cetoniques et sur les dicetones 1.2. Rec. Trav. Chim. Pays-Bas. Belg. 23, 169-172.
12. Kang Y.H., Chung S.J., Kang I.J., Park J.H. and Bunger R. (2001). Intramitochondrial pyruvate attenuates hydrogen peroxide-induced apoptosis in bovine pulmonary artery endothelium. Mol. Cell Biochem. 216, 37-46.
13. Law M.R. and Hackshaw A.K. (1997). A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. Br. Med. J. 315, 841-846.
14. Lean J.M., Jagger C.J., Kirstein B., Fuller K. and Chambers T.J. (2005). Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinology 146, 728-735.
15. Lee J.Y., Kim Y.H. and Koh J.Y. (2001). Protection by pyruvate against transient forebrain ischemia in rats. J. Neurosci. 21, RC171.
16. Lee Y.J., Kang I.J., Bunger R. and Kang Y.H. (2004). Enhanced survival effect of pyruvate correlates MAPK and NF-kappaB activation in hydrogen peroxide-treated human endothelial cells. J. Appl. Physiol. 96, 793-801.
17. Maggio D., Barabani M., Pierandrei M., Macchiarulo M.C., Cecchetti R., Pedrazzoni M., Senin U. and Cherubini A. (2002). Antioxidants and bone turnover in involutional osteoporosis. J. Endocrinol. Invest. 25, 101-102.
18. Mazzio E. and Soliman K.F. (2003). Pyruvic acid cytoprotection against 1-methyl-4-phenylpyridinium, 6-hydroxydopamine and hydrogen peroxide toxicities in vitro. Neurosci. Lett. 337, 77-80.
19. Nakamichi N., Kambe Y., Oikawa H., Ogura M., Takano K., Tamaki K., Inoue M., Hinoi E. and Yoneda Y. (2005). Protection by exogenous pyruvate through a mechanism related to monocarboxylate transporters against cell death induced by hydrogen peroxide in cultured rat cortical neurons. J. Neurochem. 93, 84-93.
20. Sharma P., Karian J., Sharma S., Kiu S. and Monaghan P.D. (2003). Pyruvate ameliorates post ischemic injury of rat astrocytes and protects them against PARP mediated cell death. Brain Res. 992, 104-113.
21. Sheline C.T., Behrens M.M. and Choi D.W. (2000). Zinc-induced cortical neuronal death: contribution of energy failure attributable to loss of NAD+ and inhibition of glycolysis. J. Neurosci. 20, 3139-3146.
22. Simonian N.A. and Coyle J.T. (1996). Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36, 83-106.
23. Ying W., Chen Y., Alano C.C. and Swanson R.A. (2002). Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes. J. Cereb. Blood Flow Metab. 22, 774-779.